Outsourcing Pharma
DECEMBER 13, 2021
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
NY Times
DECEMBER 16, 2021
The ruling said the company’s owners, members of the Sackler family, could not receive protection from civil lawsuits in return for a $4.5 billion contribution.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 15, 2021
Words matter. In the pharma industry, “patient engagement” and “patient centricity” might seem like interchangeable bits of corporate jargon. But the difference between them is not like the choice between “agreeing” and “aligning” or “getting together later” and “taking this offline.” Going from the vital activity of patient engagement to the more encompassing state of patient centricity requires big steps in the evolution of new-drug discovery, development, and delivery.
Pharma Times
DECEMBER 13, 2021
A team at The Institute of Cancer Research (ICR), London and the Clinical Trials Research Unit (CTRU) at the University of Leeds adopted a new high-speed trial methodology.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Outsourcing Pharma
DECEMBER 13, 2021
The pharmaceutical company currently has several promising treatments in development for gastroenterological, dermatological, and cardiological conditions.
NY Times
DECEMBER 14, 2021
Two drugmakers have been mired for years in the pre-application phase of getting F.D.A. approval for over-the-counter use.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharma Times
DECEMBER 14, 2021
Nivolumab plus ipilmumab has been accepted as a treatment option for adult patients by NHS Scotland for patients who have previously failed fluoropyrimidine-based chemotherapy.
Outsourcing Pharma
DECEMBER 15, 2021
The artificial intelligence-driven drug discovery company has dosed its first healthy volunteer in a trial for a candidate to treat idiopathic pulmonary fibrosis.
NY Times
DECEMBER 13, 2021
Some laboratory studies suggest that molnupiravir can insert errors in DNA, which could in theory harm a developing fetus, sperm cells or children.
pharmaphorum
DECEMBER 17, 2021
The EMA’s human medicines committee has said it cannot approve Biogen and Eisai’s Alzheimer’s disease therapy Aduhelm, saying it was unconvinced by the data submitted for the drug. The companies had already indicated that the CHMP looked likely to turn down their marketing application for Aduhelm (aducanumab), but the decision nevertheless is a heavy blow, coming as take-up of the drug has pretty much stalled in the US.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharma Times
DECEMBER 16, 2021
Venetoclax is an oral once-daily treatment, which blocks the action of the B-cell lymphoma-2 protein, the presence of which helps cancer cells survive.
Outsourcing Pharma
DECEMBER 15, 2021
The Parkinsonâs Progression Markers Initiative, built using Evidation Healthâs research platform, aims to triple enrollment and recruit online participants.
NY Times
DECEMBER 14, 2021
Vuity, a once-a-day treatment that can help users see up close without affecting their long-range vision, went on the market Thursday after being approved by the F.D.A. in October.
pharmaphorum
DECEMBER 15, 2021
Incyte could be a few month away from a second FDA approval for its Opzelura cream that would make it the first medical treatment to re-pigment the skin of people with vitiligo. The FDA has kicked off a priority review of Opzelura (ruxolitinib), a JAK1/JAK2 inhibitor it approved to treat atopic dermatitis in September, and aims to decide on the vitiligo indication by 18 April next year.
Pharma Marketing Network
DECEMBER 17, 2021
The pharma industry has been slower to embrace digital technologies than other less-regulated sectors but the COVID-19 pandemic has greatly changed this long-standing mindset. In 2020 and 2021, we saw pharma forced to become more flexible and open-minded than ever before. In this article, R.J. Lewis, Founder & CEO of eHealthcare Solutions and Tap Native, offers his top ten predictions for what’s ahead for pharma in 2022.
Pharma Times
DECEMBER 13, 2021
The approval from the European Commission (EC) is based on the results of five clinical studies, involving over 2,800 patients.
Drug Patent Watch
DECEMBER 17, 2021
Annual Drug Patent Expirations for NUPLAZID Nuplazid is a drug marketed by Acadia Pharms Inc and is included in two NDAs. It is available from one supplier. There are eighteen…. The post New patent for Acadia Pharms drug NUPLAZID appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
DECEMBER 17, 2021
The EMA’s human medicines committee has said that EU member states can start to offer Pfizer’s oral antiviral Paxlovid as a treatment for people with COVID-19 outside hospital, ahead of a formal approval for the drug. The decision comes amid rising rates of infection and deaths due to COVID-19 across the EU, and with 529 new cases of the worrisome Omicron variant reported in member states yesterday, taking the total number to 3,158.
Pharma Marketing Network
DECEMBER 17, 2021
Big pharma has compelling reasons to change the way business gets done. The wave of interest in sustainability follows the value chain from top-tier pharmaceutical companies to their suppliers of every size. Leaders are hard at work focusing their efforts on how to use sustainability as a platform for innovation. Step one is to assess your corporate social responsibility (CSR) policies and ensure actions are integrated across the organization.
Pharma Times
DECEMBER 14, 2021
The public have been assured more sites, mobile units and pop-ups would be set up across the country to fulfill the vaccination pledge ahead of the original deadline of 31 January 2022.
Drug Patent Watch
DECEMBER 16, 2021
Annual Drug Patent Expirations for XERAVA Xerava is a drug marketed by Tetraphase Pharms and is included in one NDA. There are two patents protecting this drug. This drug has…. The post New patent for Tetraphase Pharms drug XERAVA appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
DECEMBER 15, 2021
Bristol-Myers Squibb’s rheumatoid arthritis drug Orencia has been approved by the FDA to prevent graft versus host disease (GvHD), a serious complication of haematopoietic stem cell transplant (HSCT) used to treat leukaemias and other blood cancers. Orencia (abatacept) becomes the first drug to be approved to prevent GvHD , a condition in which donor immune cells attack tissues in the patient receiving an HSCT, commonly known as a bone marrow transplant.
NY Times
DECEMBER 16, 2021
The decision will broaden access to medication abortion, an increasingly common method, but many conservative states are already mobilizing against it.
Outsourcing Pharma
DECEMBER 14, 2021
Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.
Pharma Times
DECEMBER 16, 2021
A warning has been issued to UK MPs from the head of NHS England that hospitalisations could exceed numbers recorded in January 2021.
pharmaphorum
DECEMBER 17, 2021
A judge in the US has rejected the bankruptcy plan proposed by Purdue Pharma to settle legal action over its role in the opioid crisis , because of the protection from civil litigation it includes for the Sackler family that owns the drugmaker. Judge Colleen McMahon has thrown out the plan in a New York court, in a move that would remove the shield handed to the Sackers in return for a $4.5 billion payout to projects intended to support victims of the opioid crisis over a nine-year period.
Drug Channels
DECEMBER 13, 2021
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2022. Click here to see the original post and comments from August 2021. The generic prescription market is being disrupted—but not by the big, bad spaceman from Seattle. Instead, consider how GoodRx is affecting patients, payers, and PBMs.
Outsourcing Pharma
DECEMBER 13, 2021
The pharma firm has gifted $1m USD to form a scholarship fund for students headed toward careers in clinical research, with the aim of increasing diversity.
Pharma Times
DECEMBER 17, 2021
The European Medicines Agency has recommended approval for use of Kineret in COVID-19 to the European Commission, which will issue a final decision.
pharmaphorum
DECEMBER 17, 2021
There is no doubt that the COVID-19 pandemic has accelerated the adopt of digital health. As this issue’s contributors discuss, the rapid transition to digital has showcase the potential of technology across the industry, but how can we continue this momentum beyond the pandemic? Read on for a look at some of the biggest stories from Frontiers Health, how digital is making healthcare more patient-friendly and key ways to optimise decentralised clinical trials.
NY Times
DECEMBER 14, 2021
The company said the pill, Paxlovid, reduced the risk of hospitalization and death by 89 percent if given within three days of the onset of symptoms.
Outsourcing Pharma
DECEMBER 17, 2021
The company has released a survey of cancer doctors; 83% of those polled believe real-world data is crucial to accelerating cancer research and treatment.
Pharma Times
DECEMBER 17, 2021
The approval follows a successful period of monitoring and patient access through the Cancer Drugs Fund.
pharmaphorum
DECEMBER 17, 2021
After three years of availability via the Cancer Drugs Fund (CDF), MSD’s checkpoint inhibitor Keytruda has now been approved for routine NHS use after surgery for people with melanoma to prevent the cancer returning. PD-1 inhibitor Keytruda (pembrolizumab) has been recommended by NICE for adjuvant treatment of adults with stage 3 melanoma that has spread to the lymph nodes, aiming to remove any cancer left behind after surgery.
Drug Channels
DECEMBER 15, 2021
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2022. Click here to see the original post and comments from August 2021. Charlotte Morabito at CNBC has put together “Why Pharmacies Overcharge,” an entertaining and provocative video on the pharmacy industry and its generic prescription pricing.
Expert insights. Personalized for you.
140 
Let's personalize your content